India Pharma - IPM Growth Remains Moderate For Three Months Now In August: Motilal Oswal

Growth was mainly driven by price hikes.

Colourful capsules arranged for photograph. (Source: Joshua Coleman /Unsplash)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

The India pharma market grew 5.8% YoY in August 2023 (versus 6.4% in July 2023 and 10.1% in August 2022). Growth was mainly driven by price hikes.

Cardiac/gastro intestinal/gynae/vitamins-mineral-nutrients grew 9%/8%/7%/7% YoY in Aug-23.

Respiratory/anti-infective therapies declined 4%/3% YoY, affecting the overall performance to some extent.

For the 12 months ending in Aug-23, IPM grew 10.1% YoY.

Prices/volume/new launches witnessed 4.7%/2.6%/2.8 % YoY growth for 12 months ending in Aug-23.

Click on the attachment to read the full report:

Motilal Oswal Pharma Update.pdf
Read Document

Also Read: Aurobindo Pharma Forays Into Indonesian Market With Brand Acquisitions

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story You must be an existing Premium User
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit. Feel free to Add NDTV Profit as trusted source on Google.
GET REGULAR UPDATES
Add us to your Preferences
Set as your preferred source on Google